To see, to know, to heal .    

Declare the past,
diagnose the present,
foretell the future (Hippocrates)

Seeing is the
beginning

Milestones
Research
About us
Career

photonamic

The name photonamic consists of photo (= light) and dynamics and thus represents the field of activity of photonamic GmbH & Co. KG ("photonamic"). The effect of light on certain molecules is manifold and ultimately leads not only to coloration, but can also lead to fluorescence or initiation of chemical reactions.
Photonamic takes advantage of these dynamics of light by using a specific molecule that is metabolized into a photosensitizer in cells or in cell assemblies or in the body. Depending on the choice of wavelength, this can lead to a wide variety of effects triggered by the light. The use of light and the application of photosensitizers is not really a new principle, but has been known and researched for decades.
photonamic has set itself the goal of researching and developing these possibilities in a targeted manner in order to derive diverse applications from them. Unlike many other approaches, the molecule primarily used by photonamic is a precursor of the actual photosensitizer, which is metabolically converted into the light-excitable molecule and exhibits the corresponding photodyna-mic properties. The resulting fascinating applications in imaging and also therapy form the core of photonamic's activities.
Through numerous collaborations and projects with partner companies, academic institutions for clinical applicability and also with corresponding equipment companies for light sources, sensors and camera systems, the diversity of these technologies can be imagined.

‍

TOP STORIES

‍

‍Press Release Orphan Status EU

Pinneberg, Germany, January 14, 2026.

Photonamic GmbH & Co. KG (Photonamic) today announced that the European

Commission has granted Orphan Drug Designation for the company's 5-aminolevulinic acid

acid (5-ALA) for the diagnosis of ovarian cancer. 5-ALA is intended for intraoperative use.

imaging agent to assist surgeons during ovarian cancer surgeries. Ovarian cancer

remains one of the most severe gynecological malignancies with a high mortality rate

due to late diagnosis and complex surgical requirements. Improved intraoperative

visualization can play a critical role in achieving more optimal tumor resection for these

patients, which may correlate to better patient outcomes. This orphan designation

underscores the potential of 5-ALA to address a critical unmet need for patients

undergoing surgery for ovarian cancer.....more

‍

‍"Marketing Authorization for Gliolan® granted in Jordan"....more

‍

‍“Phase 3 Study of 5-ALA in Meningioma Surgery Meets Primary Endpoint”....more

NEWS ARCHIVE

photonamic GmbH & Co. KG successfully obtains ManufacturingLicense under GMP

After successful completion of planned inspections by the local health authorities,photonamic GmbH & Co. KG (photonamic), a pharmaceutical company focused on thedevelopment of 5-aminolevulinic acid (5-ALA) in various applications, was granted aManufacturing License under GMP on March 27, 2024.....

"US FDA Medical Device Registration of Aladuck405/II"

SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director & President:Yoshitaka Kitao; hereinafter "SBIP"), a subsidiary company of SBI Holdings, Inc. which conductsresearch and development pharmaceuticals, etc., utilizing 5-aminolevulinic acid (*) announces todaythat the medical light source device "Aladuck405/II" (hereafter "Aladuck") ....

"NX Development Corp. ls Granted Orphan Drug Designation Status by US FDA for Gleolan® in Ovarian and Related Cancers"

Lexington, KY, March 5, 2024 -NX Development Corp. (NXDC) has achieved another milestone as we proudly announce the recent granting of orphan-drug status by the U.S. Food

.....

All press articles